▸ 19 Nov 2026, 09:40 Reinstatement to Quotation Reinstatement
▸ 19 Nov 2026, 08:32 ACW XanaMIA Alzheimers trial results Company Update
▸ 17 Nov 2026, 10:33 Suspension from Quotation Trading Halt / Suspension
▸ 13 Nov 2026, 09:25 Request for Trading Halt Other
▸ 13 Nov 2026, 09:22 Trading Halt Trading Halt / Suspension
▸ 12 Nov 2026, 16:29 Notification of cessation of securities - ACW Securities Administration
▸ 12 Nov 2026, 16:28 Update - Notification of buy-back - ACW Buybacks & Capital Management
▸ 9 Nov 2026, 16:31 Response to ASX Price Query ASX Query
▸ 28 Oct 2026, 10:57 Letter to Shareholders, Notice of AGM & Proxy Form Meetings & Governance
▸ 26 Oct 2026, 14:16 Actinogen receives $10.8m R&D tax incentive rebate from ATO Capital Raising
▸ 21 Oct 2026, 08:55 ACW pivotal Alzheimers trial database lock - results mid-Nov Company Update
▸ 19 Oct 2026, 09:57 ACW September 2026 quarterly activity report & Appendix 4C Quarterly Reports
▸ 12 Oct 2026, 12:41 Notification of buy-back - ACW Other
▸ 9 Oct 2026, 09:10 AGM date and closing date for director nominations Meetings & Governance
▸ 30 Sep 2026, 13:04 Application for quotation of securities - ACW Securities Administration
▸ 23 Sep 2026, 12:35 Options underwriting cleansing notice Securities Administration
▸ 23 Sep 2026, 12:35 Application for quotation of securities - ACW Securities Administration
▸ 23 Sep 2026, 12:34 Underwriting of unlisted options completed Securities Administration
▸ 23 Sep 2026, 08:47 ACW Alzheimers pivotal trial completes last patient visit Company Update
▸ 16 Sep 2026, 12:43 Notification of cessation of securities - ACW Securities Administration
▸ 15 Sep 2026, 14:34 Application for quotation of securities - ACW Securities Administration
▸ 11 Sep 2026, 15:54 Application for quotation of securities - ACW Securities Administration
▸ 9 Sep 2026, 12:54 Appendix 3Y-Dr Geoffrey Brooke Director Interests
▸ 9 Sep 2026, 12:40 Application for quotation of securities - ACW Securities Administration
▸ 9 Sep 2026, 10:11 ACW CMO international Xanamem presentation Presentations
▸ 8 Sep 2026, 14:52 Application for quotation of securities - ACW Securities Administration
▸ 7 Sep 2026, 16:39 Application for quotation of securities - ACW Securities Administration
▸ 4 Sep 2026, 15:55 Response to ASX Price Query ASX Query
▸ 3 Sep 2026, 15:04 Application for quotation of securities - ACW Securities Administration
▸ 1 Sep 2026, 10:14 Proposed issue of securities - ACW Securities Administration
▸ 1 Sep 2026, 10:12 ACW unlisted options fully underwritten Company Update
▸ 28 Aug 2026, 15:58 Application for quotation of securities - ACW Securities Administration
▸ 28 Aug 2026, 14:46 Appendix 3Y-Dr George Morstyn Director Interests
▸ 28 Aug 2026, 14:43 Appendix 3Y-Dr Geoffrey Brooke Director Interests
▸ 28 Aug 2026, 14:36 Application for quotation of securities - ACW Securities Administration
▸ 27 Aug 2026, 16:42 Appendix 4G Company Administration
▸ 27 Aug 2026, 16:41 Corporate Governance Statement Company Administration
▸ 27 Aug 2026, 16:27 ACW FY2026 results and outlook Financial Results
▸ 27 Aug 2026, 16:26 ACW Appendix 4E and 2026 annual report Financial Results
▸ 20 Aug 2026, 14:46 Appendix 3Y - Dr George Morstyn Director Interests
▸ 20 Aug 2026, 14:40 Application for quotation of securities - ACW Securities Administration
▸ 17 Aug 2026, 14:26 Appendix 3Y-Malcolm McComas Director Interests
▸ 17 Aug 2026, 14:14 Application for quotation of securities - ACW Securities Administration
▸ 12 Aug 2026, 09:14 ACW webinar today, The future of Alzheimers treatment Presentations
▸ 10 Aug 2026, 16:38 Updated Securities Trading Policy Company Administration
▸ 10 Aug 2026, 11:33 Application for quotation of securities - ACW Securities Administration
▸ 10 Aug 2026, 09:12 Notification of cessation of securities - ACW Securities Administration
▸ 6 Aug 2026, 08:27 ACW Bioshares presentation, strong cortisol rationale Presentations
▸ 5 Aug 2026, 12:43 Application for quotation of securities - ACW Securities Administration
▸ 5 Aug 2026, 12:08 ACW webinar on the future of Alzheimers treatment Presentations
▸ 30 Jul 2026, 10:03 June 2026 Quarterly activity report & Appendix 4C Quarterly Reports
▸ 28 Jul 2026, 15:19 Application for quotation of securities - ACW Securities Administration
▸ 21 Jul 2026, 13:41 Application for quotation of securities - ACW Securities Administration
▸ 20 Jul 2026, 09:33 Xanamem depression trial published in British J Psychiatry Company Update
▸ 13 Jul 2026, 17:24 Notification of buy-back - ACW Other
▸ 13 Jul 2026, 08:32 ACW AAIC poster presentation of XanaMIA trial baseline data Company Update
▸ 8 Jul 2026, 08:40 ACW senior management presentation at AAIC & internationally Presentations
▸ 25 Jun 2026, 14:11 Becoming a substantial holder Substantial Holders
▸ 24 Jun 2026, 13:48 Appendix 3Y x 5 Director Interests
▸ 24 Jun 2026, 13:45 Application for quotation of securities - ACW Securities Administration
▸ 23 Jun 2026, 10:39 Results of Meeting Meetings & Governance
▸ 18 Jun 2026, 15:02 Application for quotation of securities - ACW Securities Administration
▸ 18 Jun 2026, 08:57 ACW third positive XanaMIA trial data committee review Company Update
▸ 1 Jun 2026, 08:52 ACW presents XanaMIA population and screening data at ADRF Company Update
▸ 28 May 2026, 09:51 Actinogen receives positive scientific advice from EMA Company Update
▸ 21 May 2026, 14:54 Application for quotation of securities - ACW Securities Administration
▸ 21 May 2026, 14:44 Letter to Shareholders, Notice of GM & Proxy Form Meetings & Governance
▸ 18 May 2026, 14:29 Application for quotation of securities - ACW Securities Administration
▸ 13 May 2026, 10:16 ACW CEO options exercise and expiry reminder Securities Administration
▸ 13 May 2026, 10:12 Appendix 3Y - Dr Steven Gourlay Director Interests
▸ 13 May 2026, 10:08 Application for quotation of securities - ACW Securities Administration
▸ 11 May 2026, 11:44 Application for quotation of securities - ACW Securities Administration
▸ 4 May 2026, 08:17 Notification of cessation of securities - ACW Securities Administration
▸ 29 Apr 2026, 09:17 Correction-March2026 quarterly activity report & Appendix 4C Quarterly Reports
▸ 29 Apr 2026, 09:05 ACW December 2025 quarterly activity report & Appendix 4C Quarterly Reports
▸ 2 Apr 2026, 10:53 Notification of buy-back - ACW Other
▸ 1 Apr 2026, 08:59 ACW XanaMIA Alzheimers open label trial commences Company Update
▸ 26 Mar 2026, 14:06 Appendix 3Y x 5 Director Interests
▸ 26 Mar 2026, 13:55 Cleansing Notice Securities Administration
▸ 26 Mar 2026, 13:50 Application for quotation of securities - ACW Securities Administration
▸ 18 Mar 2026, 10:50 Results of General Meeting Meetings & Governance
▸ 16 Mar 2026, 09:04 CEO loan-funded long-term incentive shares amendment Company Administration
▸ 5 Mar 2026, 14:42 Application for quotation of securities - ACW Securities Administration
▸ 2 Mar 2026, 09:10 Application for quotation of securities - ACW Securities Administration
▸ 27 Feb 2026, 09:33 ACW successfully completes $16.8m Placement and SPP Capital Raising
▸ 26 Feb 2026, 13:47 Application for quotation of securities - ACW Securities Administration
▸ 26 Feb 2026, 10:27 ACW HY26 results - XanaMIA pivotal Alzheimers trial progress Financial Results
▸ 26 Feb 2026, 10:26 Actinogen HY2025 financial report and Appendix 4D Financial Results
▸ 13 Feb 2026, 14:02 Letter to Shareholders, Notice of Meeting & Proxy Form Meetings & Governance
▸ 12 Feb 2026, 14:17 Application for quotation of securities - ACW Securities Administration
▸ 11 Feb 2026, 09:37 ACW receives further $1.9m FY2025 R&D rebate from ATO Company Administration
▸ 10 Feb 2026, 09:23 Letter to Eligible Shareholders Capital Raising
▸ 10 Feb 2026, 09:22 Share Purchase Plan Booklet Capital Raising
▸ 9 Feb 2026, 09:39 Cleansing Notice Capital Raising
▸ 9 Feb 2026, 09:35 Application for quotation of securities - ACW Securities Administration
▸ 5 Feb 2026, 13:27 Application for quotation of securities - ACW Securities Administration
▸ 2 Feb 2026, 09:57 Proposed issue of securities - ACW Securities Administration
▸ 2 Feb 2026, 09:57 Proposed issue of securities - ACW Securities Administration
▸ 2 Feb 2026, 09:57 Proposed issue of securities - ACW Securities Administration
▸ 2 Feb 2026, 09:56 ACW secures funding beyond XanaMIA AD trial final results Capital Raising